
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4579445/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Diamorphine pharmacokinetics and conversion factor estimates for intranasal diamorphine in paediatric breakthrough pain:systematic review. BMJ Supportive and Palliative Care, 2023, 13, e485-e493.	0.8	1
2	Late-onset neonatal sepsis: genetic differences by sex and involvement of the NOTCH pathway. Pediatric Research, 2023, 93, 1085-1095.	1.1	8
3	Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper. British Journal of Clinical Pharmacology, 2022, 88, 4965-4984.	1.1	21
4	Access to palivizumab among children at high risk of respiratory syncytial virus complications in English hospitals. British Journal of Clinical Pharmacology, 2022, 88, 1246-1257.	1.1	8
5	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2022, 77, 448-456.	1.3	3
6	Randomised controlled trial of fosfomycin in neonatal sepsis: pharmacokinetics and safety in relation to sodium overload. Archives of Disease in Childhood, 2022, 107, 802-810.	1.0	9
7	The impact of the COVID-19 pandemic on antimicrobial prescribing at a specialist paediatric hospital: an observational study. Journal of Antimicrobial Chemotherapy, 2022, , .	1.3	6
8	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2022, , .	1.3	2
9	Pharmacokinetic modeling and simulation to understand diamorphine doseâ€response in neonates, children, and adolescents. Paediatric Anaesthesia, 2022, 32, 716-726.	0.6	4
10	Population Pharmacokinetics of Intranasal Dexmedetomidine in Infants and Young Children. Anesthesiology, 2022, 137, 163-175.	1.3	6
11	Mechanistic Models of CD4 T Cell Homeostasis and Reconstitution in Health and Disease. , 2021, , 65-79.		0
12	Variation in Target Attainment of Beta‣actam Antibiotic Dosing Between International Pediatric Formularies. Clinical Pharmacology and Therapeutics, 2021, 109, 958-970.	2.3	5
13	IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis. Journal of Antimicrobial Chemotherapy, 2021, 76, 1855-1864.	1.3	21
14	The use of continuous electronic prescribing data to infer trends in antimicrobial consumption and estimate the impact of stewardship interventions in hospitalized children. Journal of Antimicrobial Chemotherapy, 2021, 76, 2464-2471.	1.3	10
15	Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting. Journal of Antimicrobial Chemotherapy, 2021, 76, 2252-2259.	1.3	21
16	Clinical pharmacokinetics and dose recommendations for posaconazole gastroresistant tablets in children with cystic fibrosis. Journal of Antimicrobial Chemotherapy, 2021, 76, 3247-3254.	1.3	6
17	Physiologically based modelling of tranexamic acid pharmacokinetics following intravenous, intramuscular, sub-cutaneous and oral administration in healthy volunteers. European Journal of Pharmaceutical Sciences, 2021, 164, 105893.	1.9	17
18	Safety of clonidine used for longâ€ŧerm sedation in paediatric intensive care: A systematic review. British Journal of Clinical Pharmacology, 2021, 87, 785-805.	1.1	3

#	Article	IF	CITATIONS
19	Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections. Journal of Antimicrobial Chemotherapy, 2020, 75, 135-139.	1.3	4
20	Population pharmacokinetics and pharmacodynamics of dobutamine in neonates on the first days of life. British Journal of Clinical Pharmacology, 2020, 86, 318-328.	1.1	7
21	Proposed Therapeutic Range of Treosulfan in Reduced Toxicity Pediatric Allogeneic Hematopoietic Stem Cell Transplant Conditioning: Results From a Prospective Trial. Clinical Pharmacology and Therapeutics, 2020, 108, 264-273.	2.3	22
22	β-Lactam antimicrobial Âpharmacokinetics and target attainment in critically ill patients aged 1 day to 90 years: the ABDose study. Journal of Antimicrobial Chemotherapy, 2020, 75, 3625-3634.	1.3	13
23	Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections—authors' response. Journal of Antimicrobial Chemotherapy, 2020, 75, 2713-2713.	1.3	11
24	New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT. Blood Advances, 2020, 4, 2418-2429.	2.5	24
25	Modelling of neutrophil dynamics in children receiving busulfan or treosulfan for haematopoietic stem cell transplant conditioning. British Journal of Clinical Pharmacology, 2020, 86, 1537-1549.	1.1	5
26	Using Realâ€World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokineticâ€Pharmacodynamic Study. Clinical and Translational Science, 2020, 13, 400-409.	1.5	9
27	Quantitative Clinical Pharmacology Input to SARSâ€CoVâ€2 Therapeutics Should Be Based on Robust Data. Clinical Pharmacology and Therapeutics, 2020, 108, 187-187.	2.3	3
28	Optimizing clonidine dosage for sedation in mechanically ventilated children: A pharmacokinetic simulation study. Paediatric Anaesthesia, 2019, 29, 1002-1010.	0.6	12
29	Development and external evaluation of a population pharmacokinetic model for continuous and intermittent administration of vancomycin in neonates and infants using prospectively collected data. Journal of Antimicrobial Chemotherapy, 2019, 74, 1003-1011.	1.3	20
30	What concentration of tranexamic acid is needed to inhibit fibrinolysis? A systematic review of pharmacodynamics studies. Blood Coagulation and Fibrinolysis, 2019, 30, 1-10.	0.5	101
31	Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases. British Journal of Clinical Pharmacology, 2019, 85, 1790-1797.	1.1	9
32	Revising Pediatric Vancomycin Dosing Accounting for Nephrotoxicity in a Pharmacokinetic-Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	19
33	Population Pharmacokinetics and Dosing of Milrinone After Patent Ductus Arteriosus Ligation in Preterm Infants. Pediatric Critical Care Medicine, 2019, 20, 621-629.	0.2	6
34	Pediatric pharmacokinetics of the antibiotics in the access and watch groups of the 2019 WHO model list of essential medicines for children: a systematic review. Expert Review of Clinical Pharmacology, 2019, 12, 1099-1106.	1.3	6
35	GAPPS (Grading and Assessment of Pharmacokinetic-Pharmacodynamic Studies) a critical appraisal system for antimicrobial PKPD studies – development and application in pediatric antibiotic studies. Expert Review of Clinical Pharmacology, 2019, 12, 1091-1098.	1.3	13
36	Scaling betaâ€lactam antimicrobial pharmacokinetics from early life to old age. British Journal of Clinical Pharmacology, 2019, 85, 316-346.	1.1	14

#	Article	IF	CITATIONS
37	Pharmacokinetic-pharmacodynamic modelling to investigate <i>in vitro</i> synergy between colistin and fusidic acid against MDR <i>Acinetobacter baumannii</i> . Journal of Antimicrobial Chemotherapy, 2019, 74, 961-969.	1.3	6
38	Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children. Clinical Pharmacokinetics, 2019, 58, 53-61.	1.6	35
39	Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance. Clinical Pharmacokinetics, 2019, 58, 39-52.	1.6	54
40	Pharmacodynamics and cellular accumulation of amphotericin B and miltefosine in Leishmania donovani-infected primary macrophages. Journal of Antimicrobial Chemotherapy, 2018, 73, 1314-1323.	1.3	9
41	Pharmacokinetics of Penicillin G in Preterm and Term Neonates. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	13
42	Useful pharmacodynamic endpoints in children: selection, measurement, and next steps. Pediatric Research, 2018, 83, 1095-1103.	1.1	19
43	Pharmacokinetic studies in children: recommendations for practice and research. Archives of Disease in Childhood, 2018, 103, archdischild-2017-314506.	1.0	55
44	Pharmacokinetic and pharmacodynamic study of intranasal and intravenous dexmedetomidine. British Journal of Anaesthesia, 2018, 120, 960-968.	1.5	94
45	Dosing of Ceftriaxone and Metronidazole for Children With Severe Acute Malnutrition. Clinical Pharmacology and Therapeutics, 2018, 104, 1165-1174.	2.3	15
46	Development of a Novel Multipenicillin Assay and Assessment of the Impact of Analyte Degradation: Lessons for Scavenged Sampling in Antimicrobial Pharmacokinetic Study Design. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	20
47	Clinical T Cell Receptor Repertoire Deep Sequencing and Analysis: An Application to Monitor Immune Reconstitution Following Cord Blood Transplantation. Frontiers in Immunology, 2018, 9, 2547.	2.2	36
48	Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies. Journal of Antimicrobial Chemotherapy, 2018, 73, 1908-1916.	1.3	49
49	External Evaluation of a Centamicin Infant Population Pharmacokinetic Model Using Data from a National Electronic Health Record Database. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	5
50	Comment on "Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials― Clinical Pharmacokinetics, 2018, 57, 1471-1472.	1.6	2
51	Predicting CD4 T ell Reconstitution Following Pediatric Hematopoietic Stem Cell Transplantation. Clinical Pharmacology and Therapeutics, 2017, 102, 349-357.	2.3	17
52	Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?. British Journal of Clinical Pharmacology, 2017, 83, 777-790.	1.1	88
53	The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. Drugs, 2017, 77, 941-950.	4.9	12
54	A highly sensitive method for the simultaneous UHPLC–MS/MS analysis of clonidine, morphine, midazolam and their metabolites in blood plasma using HFIP as the eluent additive. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1052, 150-157.	1.2	10

#	Article	IF	CITATIONS
55	The CLOSED trial; CLOnidine compared with midazolam for SEDation of paediatric patients in the intensive care unit: study protocol for a multicentre randomised controlled trial. BMJ Open, 2017, 7, e016031.	0.8	12
56	Understanding and applying pharmacometric modelling and simulation in clinical practice and research. British Journal of Clinical Pharmacology, 2017, 83, 247-254.	1.1	74
57	Liquid chromatography–tandem mass spectrometry for the simultaneous quantitation of ceftriaxone, metronidazole and hydroxymetronidazole in plasma from seriously ill, severely malnourished children. Wellcome Open Research, 2017, 2, 43.	0.9	9
58	AUGMENTED RENAL CLEARANCE IMPLIES A NEED FOR INCREASED AMOXICILLIN-CLAVULANATE DOSING IN CRITICALLY ILL CHILDREN. Archives of Disease in Childhood, 2016, 101, e1.15-e1.	1.0	0
59	Development and Evaluation of a Gentamicin Pharmacokinetic Model That Facilitates Opportunistic Gentamicin Therapeutic Drug Monitoring in Neonates and Infants. Antimicrobial Agents and Chemotherapy, 2016, 60, 4869-4877.	1.4	51
60	Pharmacokinetic Reason for Negative Results of Clonidine Sedation in Long-Term-Ventilated Neonates and Infants. Pediatric Critical Care Medicine, 2015, 16, 92-93.	0.2	8
61	Augmented Renal Clearance Implies a Need for Increased Amoxicillin-Clavulanic Acid Dosing in Critically Ill Children. Antimicrobial Agents and Chemotherapy, 2015, 59, 7027-7035.	1.4	71
62	Comment on Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design. Clinical Pharmacokinetics, 2015, 54, 1287-1288.	1.6	11
63	Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology. Advanced Drug Delivery Reviews, 2014, 73, 127-139.	6.6	33
64	Population Pharmacokinetics of Tobramycin in Patients With and Without Cystic Fibrosis. Clinical Pharmacokinetics, 2013, 52, 289-301.	1.6	59
65	Mathematical modelling to restore circulating IGF-1 concentrations in children with Crohn's disease-induced growth failure: a pharmacokinetic study. BMJ Open, 2013, 3, e002737.	0.8	13
66	Pharmacokinetics and Pharmacodynamics of Oseltamivir in Neonates, Infants and Children. Infectious Disorders - Drug Targets, 2013, 13, 6-14.	0.4	5
67	Short versus Long Infusion of Meropenem in Very-Low-Birth-Weight Neonates. Antimicrobial Agents and Chemotherapy, 2012, 56, 4760-4764.	1.4	41
68	Antibiotic dosing in children in Europe. Current Opinion in Infectious Diseases, 2012, 25, 235-242.	1.3	28
69	Oseltamivir Pharmacokinetics and Clinical Experience in Neonates and Infants during an Outbreak of H1N1 Influenza A Virus Infection in a Neonatal Intensive Care Unit. Antimicrobial Agents and Chemotherapy, 2012, 56, 3833-3840.	1.4	24
70	Diclofenac pharmacokinetic metaâ€analysis and dose recommendations for surgical pain in children aged 1–12 years. Paediatric Anaesthesia, 2011, 21, 316-324.	0.6	35
71	Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial. Trials, 2011, 12, 215.	0.7	27
72	A Population Pharmacokinetic/Pharmacodynamic Model of Methotrexate and Mucositis Scores in Osteosarcoma. Therapeutic Drug Monitoring, 2011, 33, 711-718.	1.0	42

#	Article	IF	CITATIONS
73	Pharmacokinetic–pharmacodynamic modeling of the hypotensive effect of remifentanil in infants undergoing cranioplasty. Paediatric Anaesthesia, 2010, 20, 7-18.	0.6	53
74	Prospective observational study of adverse drug reactions to diclofenac in children. British Journal of Clinical Pharmacology, 2009, 68, 243-251.	1.1	19
75	Population pharmacokinetics of oral diclofenac for acute pain in children. British Journal of Clinical Pharmacology, 2008, 66, 846-853.	1.1	23
76	Paediatric formulations—Getting to the heart of the problem. International Journal of Pharmaceutics, 2005, 300, 56-66.	2.6	163
77	Poor Formulation Information in Published Pediatric Drug Trials. Pediatrics, 2005, 116, e559-e562.	1.0	28
78	Liquid chromatography–tandem mass spectrometry for the simultaneous quantitation of ceftriaxone, metronidazole and hydroxymetronidazole in plasma from seriously ill, severely malnourished children. Wellcome Open Research, 0, 2, 43.	0.9	8
79	Epstein-Barr Virus Reactivation After Paediatric Haematopoietic Stem Cell Transplantation: Risk Factors and Sensitivity Analysis of Mathematical Model. Frontiers in Immunology, 0, 13, .	2.2	2